LRP6 and osteogenesis imperfecta: Because both trabecular and cortical bone mass were increased by the Lrp5A213V/A213V genotype to a similar extent in wild-type and Wnt1G177C/G177C mice and because we did not observe skeletal fractures in 24-week-old Wnt1G177C/G177C; Lrp5A213V/+ or Wnt1G177C/G177C; Lrp5A213V/A/213V mice, it is reasonable to speculate that antibodies neutralizing sclerostin can mediate a beneficial osteoanabolic effect in OI-XV patients, especially when taken into consideration that these will interfere not only with the binding of sclerostin to LRP5 but also with LRP6.